NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company’s web site at www.novabaypharma.com.
- 17 years ago
QualityStocks
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – BluSky AI Inc. (OTC: BSAI) Launches SkyMod Series for Scalable, Rapid-Deploy AI Datacenters
BluSky AI (OTC: BSAI) announced the completion of its modular AI datacenter infrastructure, unveiling the…
-
Newton Golf Company Inc. (NASDAQ: NWTG) Unveils Lighter Shaft amid Women’s Golf Boom
Women make up roughly 28% of on-course golfers in the United States, a historic high.…
-
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and…